S

Shandong Boan Biotechnology Co Ltd
HKEX:6955

Watchlist Manager
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Watchlist
Price: 7.9 HKD 3.67% Market Closed
Market Cap: 4.2B HKD
Have any thoughts about
Shandong Boan Biotechnology Co Ltd?
Write Note

Shandong Boan Biotechnology Co Ltd
Short-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Shandong Boan Biotechnology Co Ltd
Short-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
S
Shandong Boan Biotechnology Co Ltd
HKEX:6955
Short-Term Debt
ÂĄ117.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Short-Term Debt
ÂĄ4.7B
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Short-Term Debt
ÂĄ0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Short-Term Debt
ÂĄ173.1m
CAGR 3-Years
31%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Short-Term Debt
ÂĄ168.4k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Short-Term Debt
ÂĄ3.4B
CAGR 3-Years
86%
CAGR 5-Years
7%
CAGR 10-Years
52%
No Stocks Found

Shandong Boan Biotechnology Co Ltd
Glance View

Market Cap
4B HKD
Industry
Biotechnology

Shandong Boan Biotechnology Co., Ltd. operates as a biopharmaceutical company that specializes in therapeutic antibody development, manufacturing and commercialization. The company is headquartered in Yantai, Shandong and currently employs 631 full-time employees. The company went IPO on 2022-12-30. The firm is engaged in the development, production and commercialisation of therapeutic antibodies, focusing on the therapeutic areas of oncology, metabolism, autoimmunology and ophthalmology. The firm has three main technology platforms: a fully human antibody transgenic mouse and phage display technology platform, a bispecific T-cell Engager technology platform, and an antibody drug coupling (ADC) technology platform. The firm operates mainly in the domestic Chinese market and overseas markets.

Intrinsic Value
12.85 HKD
Undervaluation 39%
Intrinsic Value
Price
S

See Also

What is Shandong Boan Biotechnology Co Ltd's Short-Term Debt?
Short-Term Debt
117.8m CNY

Based on the financial report for Dec 31, 2023, Shandong Boan Biotechnology Co Ltd's Short-Term Debt amounts to 117.8m CNY.

What is Shandong Boan Biotechnology Co Ltd's Short-Term Debt growth rate?
Short-Term Debt CAGR 1Y
1 545%

Over the last year, the Short-Term Debt growth was 1 545%.

Back to Top